drugset / Trial / NCT00072865

Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer

NCT00072865 ↗

Phase 2 Completed 50 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a nonrandomized study of pemetrexed plus carboplatin, with the primary objective of determining the efficacy of the combination in tumor reduction, in patients with locally advanced or metastatic breast cancer.

Timeline

Start
2003-06
Primary completion
—
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — —
Subject Pemetrexed Small molecule — —